Form 6-K Radiopharm Theranostics For: Aug 20

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of August 2026

 

Commission File Number: 001-41621

 

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

RADIOPHARM THERANOSTICS LIMITED

 

EXPLANATORY NOTE

 

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 20, 2026 titled:

 

“RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial”

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This Form 6-K, including the exhibits hereto, is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178) and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934.

 

 

EXHIBITS

 

Exhibit Number		Description
99.1		RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	RADIOPHARM THERANOSTICS LIMITED
Date: August 20, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

 

 

ATTACHMENTS / EXHIBITS

RAD ADVANCES TO COHORT 4 IN 177LU-RAD202 PHASE 1 HEAT TRIAL

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Radiopharm trial advances to higher dose in HER2+ cancer study
• Kantor Penerjemah Tersumpah Expands Multilingual Certified Translation and Legalization Services
• Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial